Bold Therapeutics Joins Metals in Medicine Gordon Research Conference

The conference, titled "Building Momentum for Targeted Metal-Based Therapeutics and Diagnostics," serves as a high-level forum for sharing pre-publication research. Dr. Maria Contel, conference co-chair and professor at Brooklyn College, noted that Harrypersad’s leadership session offers a critical platform for industry experts to address the hurdles inherent in clinical development. For Bold Therapeutics, the event marks an opportunity to strengthen its visibility among top-tier scientists and cultivate potential research partnerships.

Bold Therapeutics currently leads the sector with BOLD-100, its primary Ruthenium-III based clinical-stage therapy. The drug is undergoing a global Phase 2 randomized controlled trial across Canada, the European Union, and South Korea. Beyond its primary investigation into anticancer efficacy, the trial evaluates the compound’s neuroprotective capabilities. Early clinical data suggest that BOLD-100 provides significant relief for patients suffering from chemotherapy-induced peripheral neuropathy, particularly within gastrointestinal cancer treatments.